Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 9
2004 9
2005 17
2006 5
2007 10
2008 3
2009 8
2010 13
2011 16
2012 13
2013 16
2014 7
2015 12
2016 11
2017 9
2018 6
2019 5
2020 6
2021 8
2022 6
2023 4
2024 8
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, Zeillinger R, Schmitt WD, Sehouli J, Kulbe H, Fleischmann M, Ray-Coquard I, Zeimet A, Raspagliesi F, Zamagni C, Vergote I, Lorusso D, Concin N, Bullinger L, Braicu EI, Damm F. Arends CM, et al. Among authors: zeillinger r. Leukemia. 2024 Jun;38(6):1378-1389. doi: 10.1038/s41375-024-02253-3. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38637689 Free PMC article. Clinical Trial.
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Obermayr E, Mohr T, Schuster E, Braicu EI, Taube E, Sehouli J, Vergote I, Pujade-Lauraine E, Ray-Coquard I, Harter P, Wimberger P, Joly-Lobbedez F, Mahner S, Moll UM, Concin N, Zeillinger R. Obermayr E, et al. Among authors: zeillinger r. Int J Cancer. 2024 Sep 15;155(6):1128-1138. doi: 10.1002/ijc.34978. Epub 2024 Apr 27. Int J Cancer. 2024. PMID: 38676430 Clinical Trial.
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Among authors: zeillinger r. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.
Association of myeloperoxidase with ovarian cancer.
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF. Castillo-Tong DC, et al. Among authors: zeillinger r. Tumour Biol. 2014 Jan;35(1):141-8. doi: 10.1007/s13277-013-1017-3. Epub 2013 Jul 27. Tumour Biol. 2014. PMID: 23893381 Free PMC article.
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Fromhage G, Obermayr E, Bednarz-Knoll N, Van Gorp T, Welsch E, Polterauer S, Braicu EI, Mahner S, Sehouli J, Vergote I, Concin N, Kurtz S, Steinbiss S, Torge A, Zeillinger R, Wölber L, Brandt B. Fromhage G, et al. Among authors: zeillinger r. Int J Cancer. 2024 Sep 1;155(5):934-945. doi: 10.1002/ijc.34976. Epub 2024 May 6. Int J Cancer. 2024. PMID: 38709956
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, Heinze G, Yang WL, Bast RC, Sehouli J, Braicu EI, Vergote I, Van Gorp T, Mahner S, Paspalj V, Grimm C, Obermayr E, Schuster E, Holzer B, Rousseau F, Schymkowitz J, Concin N, Zeillinger R. Heinzl N, et al. Among authors: zeillinger r. Oncogene. 2023 Aug;42(33):2473-2484. doi: 10.1038/s41388-023-02758-8. Epub 2023 Jul 4. Oncogene. 2023. PMID: 37402882
GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.
Concin N, Braicu I, Combe P, Berger R, Ray-Coquard I, Joly F, Harter P, Canzler U, Selle F, Mahner S, Ignatov A, Sehouli J, Pujade-Lauraine E, Zeimet AG, Schmitt WD, Van Nieuwenhuysen E, Vanderstichele A, Dobbelstein M, Kramer D, Ulmer H, Zeillinger R, Obermayr E, Heinzl N, Marth C, Moll UM, Vergote I. Concin N, et al. Among authors: zeillinger r. Clin Cancer Res. 2025 May 28. doi: 10.1158/1078-0432.CCR-24-3705. Online ahead of print. Clin Cancer Res. 2025. PMID: 40435111
190 results